ValuEngine downgraded shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) from a hold rating to a sell rating in a report published on Monday morning.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Strongbridge Biopharma PLC from a buy rating to a hold rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. assumed coverage on shares of Strongbridge Biopharma PLC in a report on Thursday, August 10th. They set an outperform rating and a $12.00 price objective on the stock. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Strongbridge Biopharma PLC has an average rating of Hold and an average price target of $11.94.

Strongbridge Biopharma PLC (NASDAQ SBBP) traded up 3.689% during trading on Monday, hitting $6.325. The stock had a trading volume of 236,922 shares. Strongbridge Biopharma PLC has a 12 month low of $2.00 and a 12 month high of $8.85. The stock’s market cap is $223.49 million. The firm has a 50 day moving average of $6.84 and a 200-day moving average of $5.68.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.84 million. Equities analysts predict that Strongbridge Biopharma PLC will post ($2.48) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Strongbridge Biopharma PLC (SBBP) Downgraded by ValuEngine” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/10/05/strongbridge-biopharma-plc-sbbp-downgraded-by-valuengine.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Broadfin Capital LLC grew its holdings in shares of Strongbridge Biopharma PLC by 3.0% during the first quarter. Broadfin Capital LLC now owns 2,981,706 shares of the biotechnology company’s stock valued at $14,163,000 after buying an additional 87,125 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at $114,000. Rhumbline Advisers purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at $154,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at $332,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Strongbridge Biopharma PLC during the second quarter valued at $277,000. 63.65% of the stock is currently owned by hedge funds and other institutional investors.

Strongbridge Biopharma PLC Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related stocks with our FREE daily email newsletter.